Aptose Biosciences (APTO) is a science-driven biotechnology company advancing first-in-class agents to treat life threatening hematologic malignancies, which includes acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), as well as various non-Hodgkin’s lumphomas (NHL). APTO also targets a variety of cancer.
Now, there are two major catalysts for this biotech stock, there was a nice move Moday. First, Aptose Biosciences (APTO) presented promising preclinical data for experimenting drug CG-806 at the American Society of Hematology (ASH) meeting on Sudnay. Second, Merck announce Monday that it planned to acquire ArQule for $2.7 million, ArQule’s lead candidate ARQ 531 is a Bruton’s tyrosine kinase (BTK) inhibitor just like CG-806.
Merck’s acquisition of ArQule underscores the interest in next generation BTK inhibitors among big drugmakers. and Aptose’s preclinical data shows that the drug is more effective than first-generation BTK inhibitor Imbruvica in treating chronic lymphocytic leukemia (CLL)
Aptose Biosciences (APTO) Analysis
Aptose Biosciences (APTO) announced an equity offering of common shares and shares plummeted 13% after hours.
$APTO If you look purely at the technical trading of APTO, everything is lined up on the 1 hour chart for this to shoot past the resistance price and recent high of 4.54. Technicals aside, the reason why this will blow up is because of the value of their pipeline, especially the BTK Inhibitor which is being bought up by larger companies. Merck just put in a 2Bil+ bid for ARQL. Eli Lilly purchased Loxo Oncology for their BTK inhibitor, LOXO-305. Smart money has already came in and more smart money will keep coming depending on what happens with the possibility of the ARQL second bid. Money from ARQL will move into APTO. This is a great short/ mid/ long term investment.
Copetrades – StockTwits
Aptose Biosciences Final Thoughts
This is an exclusive opportunity which is open for you right now, you have a chance to join the wall street insiders and profit like they do; before the market!
Now remember, this is confidential information and may be at risk of getting shut down, therefore we are ONLY allowing the first 500 people to watch the special replay on a first come, first served basis.
Get access now before the replay goes offline.
